Entomopathogenic fungi such as Metarhizium robertsii occupy a peculiar niche in the microbial world. Unlike bacteria that are ingested by their hosts, these fungi attack directly through the insect cuticle, germinating on the outer surface, penetrating the chitinous armor, and then proliferating in the open circulatory system of the insect. That journey demands a constant stream of secreted proteins, known as effectors, which are dispatched into the host to neutralize defenses and reconfigure host physiology in ways that favor fungal growth. Effectors that cross kingdom boundaries, moving from a fungal cell into an insect body, face an unusually harsh transit. They must fold correctly, avoid degradation, and remain soluble and secretion-competent in environments that differ radically from the fungal cytoplasm. How fungi safeguard their effectors through this transition has been a persistent gap in the molecular understanding of fungal pathogenesis, and it is precisely the gap that the new study set out to fill.

The team’s attention settled on MrNIS1, an effector previously associated with the virulence of Metarhizium, and on the question of what physical state the protein must occupy to survive its journey. The answer turned out to hinge on a post-translational modification: the attachment of an acetyl group to the lysine residue at position 24 of the protein. This acetylation, the researchers found, governs both the stability of MrNIS1 and its ability to be secreted. Crucially, the modification is not a passive chemical accident but the product of a regulated enzymatic cycle. MrNIS1 physically associates with MrKAT1, an acetyltransferase that installs the acetyl mark, and with MrSIR2, a deacetylase that can remove it. The presence of paired writing and erasing enzymes implies that the fungus actively manages the acetylation state of its effector, treating lysine 24 as a molecular switch whose position determines whether MrNIS1 remains a competent weapon or degrades into uselessness.

With the regulatory logic established, the researchers traced what acetylated MrNIS1 actually does once it reaches the insect interior, and here the protein revealed its dual nature. The first target is the insect immune system, specifically the cascade that culminates in prophenoloxidase activation. In insects, prophenoloxidase is the zymogen at the heart of melanization, the process by which invading pathogens are encased in dark, toxic melanin deposits and immobilized. Melanization is one of the most rapid and potent humoral defenses available to an insect lacking adaptive antibodies, and blocking it is a high-value objective for any pathogen. The study shows that MrNIS1 binds directly to the serine protease SPS, a component of the activation cascade, and by doing so prevents the chain of proteolytic events that would otherwise activate prophenoloxidase. The consequence is a suppressed melanization response, leaving the fungus freer to proliferate in the hemolymph without facing the melanin wall that healthy insects throw around invaders.

The second target lies far from immunity, in the endocrine machinery of development. MrNIS1 also interacts with ERP, an evolutionarily conserved cholesterol transporter. Cholesterol trafficking is a prerequisite for the biosynthesis of ecdysteroids, the molting hormones that orchestrate insect development, timing each larval stage and the transitions between them. By disrupting the function of ERP, MrNIS1 interferes with ecdysteroid production, and the downstream effects are visible in the host: larval growth is impaired and cuticle synthesis, which depends on properly timed hormonal cues, is compromised. In effect, a single fungal protein reaches into two disconnected physiological systems, one defensive and one developmental, and degrades both. That a secreted effector can achieve this dual targeting with a single polypeptide chain underscores how economical fungal virulence strategies can be, and it suggests that other cross-kingdom effectors may harbor similarly layered functions awaiting discovery.

Perhaps the most striking finding is how generalizable the second interaction is. The MrNIS1-ERP interaction proved to be functionally conserved across three of the largest insect orders: Lepidoptera, the moths and butterflies; Coleoptera, the beetles; and Diptera, the flies. Conservation across such distantly related insects indicates that the cholesterol transporter retains structural features that the fungal effector can recognize regardless of host lineage, which is exactly the property a broad-spectrum pathogen would need. For a fungus like Metarhizium robertsii, whose natural host range spans many insect species, an effector that works against a conserved developmental component multiplies its utility. From an applied perspective, this breadth is equally significant, because biocontrol agents are most valuable when they can act across the diverse pest species that attack crops, and an effector with cross-order activity is a ready-made template for such breadth.

The regulatory system itself also travels well between fungal species. When the researchers expressed MrNIS1 heterologously in Beauveria bassiana, another insect-pathogenic fungus widely used in commercial biocontrol, the KAT1/SIR2 acetylation-deacetylation system proved conserved and functional in its new host. MrNIS1 behaved there as what the authors describe as a portable virulence module, significantly enhancing the pathogenic efficacy of the recipient fungus. This experiment carries a double implication. Scientifically, it shows that the acetylation-dependent mechanism for preserving effector competence is not an idiosyncrasy of Metarhizium but a conserved strategy within insect-pathogenic fungi. Practically, it demonstrates that virulence factors can be transferred between fungal biocontrol agents along with their regulatory machinery, opening a rational engineering path: rather than selecting for virulence by trial and error, developers could install defined effector modules and their accompanying modification systems into established biocontrol strains.

The conceptual weight of the study lies in its reframing of lysine acetylation. Best known as a regulator of chromatin structure and enzyme activity within cells, acetylation here emerges as a guardian of protein competence outside the producing organism, a quality-control mark that preserves a secreted effector during the perilous transit between kingdoms. The interplay between MrKAT1 and MrSIR2 suggests a dynamic, tunable system rather than a one-time modification, raising questions the study leaves open: when during infection is the mark installed, whether the deacetylase acts to recycle or inactivate the effector, and how the fungus coordinates the acetylation state of its broader secretome. Answering these questions could reveal a general layer of regulation governing fungal effectors, with implications that extend beyond entomopathogenic fungi to plant pathogens and medically important species that likewise depend on secreted proteins to subvert their hosts.

For agriculture, the near-term significance is concrete. Metarhizium and Beauveria formulations are already deployed against pests as alternatives to chemical insecticides, but their adoption is limited by variable efficacy and slow kill relative to synthetic chemistry. Understanding that a single acetylated effector simultaneously suppresses immune melanization and disrupts ecdysteroid-driven development explains part of the mechanistic basis of fungal killing and identifies two host processes whose manipulation accelerates it. The conserved MrNIS1-ERP interaction offers a target for screening or engineering, while the demonstrated portability of the effector and its KAT1/SIR2 regulatory pair provides a direct method for building it into commercial strains. At the same time, the work is a reminder of the sophistication of cross-kingdom molecular conflict: a fungus has evolved, on one protein, a switch that keeps the weapon armed in transit, a grip on the host’s immune cascade, and a hand on the hormonal throttle of the host’s own growth. Decoding that switch, the authors argue, illuminates a conserved strategy of fungal pathogenesis and supplies tangible targets for the next generation of microbial biocontrol agents.

Subject of Research: Acetylation-dependent dual targeting of insect immunity and development by the fungal effector MrNIS1

Article Title: Acetylation enables a dual-targeting fungal effector to inhibit insect immunity and development

Article References: Wang, Y., Dong, Y., Zhang, Y., Wu, S., Yu, D., Yang, G., Gao, S., Yang, Y., Dong, S., Qin, L., & Huang, B. (2026). Acetylation enables a dual-targeting fungal effector to inhibit insect immunity and development. PLOS Pathogens, 22(10), e1014680. https://doi.org/10.1371/journal.ppat.1014680

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014680

Keywords: Metarhizium robertsii, effector protein, lysine acetylation, insect immunity, melanization, prophenoloxidase, ecdysteroid biosynthesis, cholesterol transporter, biocontrol, Beauveria bassiana, fungal pathogenesis, cross-kingdom infection

The modification at the heart of the study is deceptively simple. Lysine is one of the twenty amino acids that make up proteins, and when a small acetyl group is attached to its side chain, the physics of the protein changes. Acetylation can neutralize a positive charge, alter how the protein folds, reshape the surfaces it uses to bind partners, change how long it survives in circulation, and modulate its enzymatic activity. Because a single protein can carry acetyl groups at many different lysine positions, each with potentially distinct consequences, the modification multiplies the functional diversity of the proteome many times over. In cells and tissues, lysine acetylation is famous as a regulator of gene expression and metabolism; in blood plasma, the protein-rich, cell-free fraction of blood, it has been far less systematically explored, particularly in the context of neurodegenerative disease.

To capture this hidden layer, the researchers turned to mass spectrometry, the workhorse technology of modern proteomics. In this approach, proteins extracted from plasma are broken into short peptide fragments, which are then separated by liquid chromatography and fired into a mass spectrometer. The instrument fragments each peptide further and records the resulting spectra, from which the identity of the parent protein and the exact position of any chemical modification can be inferred. Crucially, the team enriched specifically for acetylated peptides before analysis, a step that is essential because acetylated peptides are typically rare amid the overwhelming abundance of unmodified material in plasma. Without such enrichment, the signal from these modified peptides would drown in noise.

The scale of the resulting dataset is what sets the study apart. From plasma samples obtained from twenty Alzheimer’s disease patients and twenty age-matched controls, the researchers acquired more than 7,600 independent tandem mass spectrometry spectral measurements corresponding to 350 unique lysine acetylation sites. Each of those sites represents a specific lysine residue on a specific plasma protein where an acetyl group was detected and localized. This is not merely a catalog of proteins present in blood, which earlier plasma proteomics efforts have assembled in depth, but a map of where on each protein the chemical decoration occurs, in a clinical context where such information did not previously exist.

The study is, according to its authors, the first lysine acetylation-directed proteomic landscape of Alzheimer’s-related human plasma samples. That first matters because plasma is where blood-based diagnostics for Alzheimer’s are increasingly being developed. Current leading biomarkers, such as measures of phosphorylated tau in plasma, focus on a different post-translational modification, phosphorylation, and on proteins that originate in the brain. Acetylation offers a complementary view: it reports on the state of the abundant plasma proteome itself, including lipoproteins, complement factors, coagulation proteins and carriers that mediate inflammation, lipid transport and immune signaling, all of which are increasingly implicated in Alzheimer’s pathogenesis through large-scale genetic and epidemiological studies.

Among the proteins carrying acetylation marks, apolipoproteins stand out as a biologically plausible focus. These lipid-binding proteins shuttle cholesterol and other fats through the bloodstream, and the strongest genetic risk factor for late-onset Alzheimer’s disease, the APOE gene, encodes an apolipoprotein. The study’s abbreviation list also flags low-density lipoprotein, the cholesterol-carrying particles whose biology intersects with both cardiovascular and neurodegenerative disease, suggesting that acetylation states on lipid transport machinery were among the features captured in the dataset. How acetylation alters the function of these carriers, and whether specific acetylation patterns track with disease status, are questions the dataset now makes answerable.

Perhaps the most unexpected dimension of the work lies beyond canonical proteins altogether. The mass spectrometry measurements detected acetylated peptide sequences that do not map to the standard catalog of human proteins. Instead, they correspond to short open reading frames, stretches of the genome that ribosome profiling technologies have shown are actively translated into tiny peptides even though they were long dismissed as non-coding. The idea that such non-canonical peptides circulate in plasma, and that they carry lysine acetylation marks detectable by mass spectrometry, expands the searchable space of blood-borne molecules. It hints that the plasma proteome is even less fully inventoried than assumed, and that some disease-relevant signals may reside in proteins that standard annotation pipelines ignore.

Methodologically, the study reflects the demanding craft of plasma proteomics. The authors employed filter-aided sample preparation, a technique that uses molecular-weight filters to clean and digest protein samples, and combined complementary fragmentation methods, collision-induced dissociation and higher-energy collisional dissociation, to maximize the information extracted from each peptide. Quantification was performed label-free, comparing spectral intensities across samples rather than relying on chemical tags introduced beforehand. The abbreviation NSRP1, for nuclear speckle splicing regulatory protein 1, appears in the study’s key terms, indicating that even proteins not normally thought of as plasma residents contributed identifiable acetylated peptides to the landscape.

The study design itself was deliberately controlled. Twenty patients with Alzheimer’s disease and twenty age-matched controls provide a matched comparison in which age, the strongest demographic risk factor, is held constant. The plasma samples were obtained from a commercial vendor operating under applicable regulations for the collection and handling of biological specimens, which the authors note meant separate ethics approval was not required. The work was funded by a Grant-in-Aid for Transformative Research Areas from Japan’s Ministry of Education, Culture, Sports, Science and Technology, with additional research funding from Abbott Laboratories, and one co-author is an employee of Abbott Japan, a disclosure the authors make explicitly in the paper.

What the study does not yet claim is a diagnostic test. A landscape of 350 acetylation sites across forty individuals is a foundation, not a finished clinical instrument. Validating any individual acetylation site as a biomarker will require larger and more diverse cohorts, longitudinal sampling, and confirmation that the modification patterns are reproducible across laboratories and platforms. The authors frame their contribution accordingly: as a resource that may contribute to a more extensive understanding of the biochemical properties of human plasma protein components in relation to Alzheimer’s disease pathogenesis. In a field racing toward blood-based early detection, the message of the study is that the blood itself still holds layers of information, written in chemical tags, that science is only now learning to read.

Subject of Research: Lysine acetylation profiling of plasma proteins in Alzheimer's disease using mass spectrometry

Article Title: Lysine acetylation-directed high-resolution plasma proteomic landscape of Alzheimer’s disease

Article References: Kozuka-Hata, H., Kitamura, A., Hiroki, T., Miyamura, N., Yoshimura, T., Tsumoto, K., & Oyama, M. (2026). Lysine acetylation-directed high-resolution plasma proteomic landscape of Alzheimer’s disease. Clinical Proteomics. https://doi.org/10.1186/s12014-026-09635-y

Image Credits: AI Generated

DOI: 10.1186/s12014-026-09635-y

Keywords: Alzheimer's disease, plasma proteomics, lysine acetylation, mass spectrometry, post-translational modification, apolipoprotein, short open reading frame, biomarkers, Clinical Proteomics, blood-based diagnostics, Lysine, acetylation-directed